12/30/2022 | LM | Outlook 2023: Ukraine debt deferral leads overall smaller year in LM exercises
|
3/2/2022 | IGLM | Bristol-Myers details early tender amounts and pricing, tweaks offer
|
3/2/2022 | IGLM | Bristol-Myers Squibb details early tender amounts, tweaks offer
|
2/15/2022 | IGLM | Bristol-Myers Squibb to buy notes from 22 series for up to $4 billion
|
2/22/2021 | IGLM | Bristol-Myers, Celgene to redeem 4% notes, 3.25% notes due 2023
|
2/19/2021 | IGLM | Bristol-Myers Squibb announces pricing on tender offers for 20 series
|
2/19/2021 | IGLM | Bristol-Myers Squibb gives early results of tender offers for 20 series
|
2/4/2021 | BWIGLM | Bristol-Myers starts leverage reduction goal with $4 billion tender
|
2/4/2021 | IGLM | Bristol-Myers Squibb kicks off $4 billion tender offers for 20 series
|
11/21/2019 | IGLM | Bristol-Myers announces results of exchange offers for Celgene notes
|
11/15/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
11/12/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
11/7/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
11/5/2019 | IGLM | Bristol-Myers Squibb again extends exchange offers for Celgene notes
|
11/1/2019 | IGLM | Bristol-Myers Squibb again extends exchange offers for Celgene notes
|
10/30/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
10/18/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
10/8/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
9/23/2019 | IGLM | Bristol-Myers Squibb again extends exchange offers for Celgene notes
|
8/26/2019 | IGLM | Bristol-Myers Squibb to pay down debt with divestiture proceeds
|
6/28/2019 | IGLM | Bristol-Myers extends exchange offers for Celgene notes
|
5/24/2019 | IGLM | Bristol-Myers extends exchange offers for Celgene notes
|
5/2/2019 | IGLM | Bristol-Myers gives early results of offers for Celgene notes
|
4/17/2019 | IGLM | Bristol-Myers Squibb launches exchange offer for 19 Celgene notes
|
6/21/2017 | IGLM | Bristol-Myers Squibb gets tenders for $337 million of three series
|
6/20/2017 | IGLM | Bristol-Myers prices tender offer for 5.875%, 6.125%, 6.875% debt
|
6/14/2017 | IGLM | Bristol-Myers tenders for 5.875% and 6.125% notes, 6.875% debentures
|
6/2/2015 | EULM | Bristol-Myers to redeem 4.625% senior notes at €1,291.25 per €1,000
|
5/27/2015 | IGLM | Bristol-Myers wraps oversubscribed tender offer for $500 million notes
|
5/12/2015 | IGLM | Bristol-Myers increases tender to $500 million, gives early results
|
5/5/2015 | EULM | Bristol-Myers calls all 4.375% notes due 2016, 4.625% notes due 2021
|
4/29/2015 | EULM | Bristol-Myers to redeem €1 billion senior notes via new notes offering
|
4/28/2015 | IGLM | Bristol-Myers tenders for up to $400 million of four series of notes
|
1/31/2014 | IGLM | Bristol-Myers to redeem $582.06 million 5.45% notes due 2018
|
8/13/2012 | CVLM | Amylin announces change-of-control put option for 3% convertibles
|
12/3/2010 | IGLM | Bristol-Myers records $1.09 billion tenders in oversubscribed offer
|
11/18/2010 | IGLM | Bristol-Myers Squibb sets tender offer prices for 6.125%, 5.875% notes
|
11/17/2010 | IGLM | Bristol-Myers Squibb gets tenders for $1.09 billion of notes so far
|
11/3/2010 | IGLM | Bristol-Myers Squibb tenders for $750 million of four note series
|